Who are azithromycin and cefixime's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azithromycin-and-cefixime.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

azithromycin and cefixime — Competitive Intelligence Brief

azithromycin and cefixime (azithromycin and cefixime) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antibiotic (macrolide + third-generation cephalosporin). Area: Infectious Disease.

marketed Combination antibiotic (macrolide + third-generation cephalosporin) Bacterial 50S ribosome (azithromycin); bacterial cell wall peptidoglycan (cefixime) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

azithromycin and cefixime (azithromycin and cefixime) — Sheba Medical Center. This combination uses azithromycin (a macrolide antibiotic) and cefixime (a third-generation cephalosporin) to inhibit bacterial protein synthesis and cell wall synthesis, respectively, providing broad-spectrum coverage against multiple pathogens.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
azithromycin and cefixime TARGET	azithromycin and cefixime	Sheba Medical Center	marketed	Combination antibiotic (macrolide + third-generation cephalosporin)	Bacterial 50S ribosome (azithromycin); bacterial cell wall peptidoglycan (cefixime)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antibiotic (macrolide + third-generation cephalosporin) class)

Sheba Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). azithromycin and cefixime — Competitive Intelligence Brief. https://druglandscape.com/ci/azithromycin-and-cefixime. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab